SCHEMBL2632938

SCHEMBL2632938

CNc1nc2ccccc2nc1N1CCNCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.50
HTR3A P46098 3/20 0.49
HRH4 Q9H3N8 1/20 0.48
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPK1 P28482 2/20 0.47
HSD17B10 Q99714 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
TSHR P16473 2/20 0.47
MAPT P10636 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
GFER P55789 1/20 0.47
CYP1A2 P05177 3/20 0.46
ADRB1 P08588 3/20 0.46
CYP3A4 P08684 2/20 0.46
HTR3E A5X5Y0 2/20 0.46
HTR3B O95264 2/20 0.46
HTR3D Q70Z44 2/20 0.46
HTR3C Q8WXA8 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28610794 0.83 HSD17B10 (0.67) HTR6HTR3AKDM4EALDH1A1MAPK1
SCHEMBL15566411 0.81 GPR6 (0.60) HTR6
Hydrochloric Acid SCHEMBL15566557 0.80 GPR6 (0.59) HTR6
Hydrochloric Acid SCHEMBL15566736 0.80 GPR6 (0.59) HTR6
SCHEMBL4472647 0.79 CYP1A2 (0.72) HTR6HTR3AHRH4KDM4EALDH1A1
SCHEMBL31652347 0.79 CYP1A2 (0.72) HTR6HTR3AHRH4KDM4EALDH1A1
SCHEMBL188615 0.76 MAPT (0.64) HTR6KDM4EALDH1A1MAPK1HSD17B10
SCHEMBL4307835 0.76 HTR3A (0.66) HTR6HTR3AHRH4KDM4EALDH1A1
SCHEMBL31143046 0.76 HTR3A (0.66) HTR6HTR3AHRH4KDM4EALDH1A1
SCHEMBL15567350 0.76 GPR6 (0.64) HTR6HTR3ACYP1A2CYP3A4HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2056829-B9 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS INC (US) 2012-09-26 EP disclosed
EP-2056829-B1 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS INC (US) 2012-01-04 EP disclosed